Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus

Glucagon is an important pancreatic hormone, released into blood circulation by alpha cells of the islet of Langerhans. Glucagon induces gluconeogenesis and glycogenolysis in hepatocytes, leading to an increase in hepatic glucose production and subsequently hyperglycemia in susceptible individuals. Hyperglucagonemia is a constant feature in patients with T2DM. A number of bioactive agents that can block glucagon receptor have been identified. These glucagon receptor antagonists can reduce the hyperglycemia associated with exogenous glucagon administration in normal as well as diabetic subjects. Glucagon receptor antagonists include isoserine and beta-alanine derivatives, bicyclic 19-residue peptide BI-32169, Des-His1-[Glu9] glucagon amide and related compounds, 5-hydroxyalkyl-4-phenylpyridines, N-[3-cano-6- (1,1 dimethylpropyl)-4,5,6,7-tetrahydro-1-benzothien-2-yl]-2-ethylbutamide, Skyrin and NNC 250926. The absorption, dosage, catabolism, excretion and medicinal chemistry of these agents are the subject of this review. It emphasizes the role of glucagon in glucose homeostasis and how it could be applied as a novel tool for the management of diabetes mellitus by blocking its receptors with either monoclonal antibodies, peptide and non-peptide antagonists or gene knockout techniques.

[1]  T. Kieffer,et al.  Targeting the glucagon receptor family for diabetes and obesity therapy. , 2012, Pharmacology & therapeutics.

[2]  M. Coffernils,et al.  Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[3]  V. Ding,et al.  Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists. , 2011, Bioorganic & medicinal chemistry letters.

[4]  J. Ampuero,et al.  Sentinel Surveillance of Influenza-Like-Illness in Two Cities of the Tropical Country of Ecuador: 2006–2010 , 2011, PloS one.

[5]  C. Hamm,et al.  The impact of epigenomics on future drug design and new therapies. , 2011, Drug discovery today.

[6]  N. Billestrup,et al.  Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus , 2011, Molecular Medicine.

[7]  M. J. Charron,et al.  Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice , 2011, Diabetes.

[8]  G. Almouzni,et al.  Nucleosome dynamics and histone variants. , 2010, Essays in biochemistry.

[9]  R. Simmons,et al.  Epigenetic mechanisms in the development of type 2 diabetes , 2010, Trends in Endocrinology & Metabolism.

[10]  M. Marahiel,et al.  The glucagon receptor antagonist BI‐32169 constitutes a new class of lasso peptides , 2010, FEBS letters.

[11]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[12]  I. Pogribny,et al.  DNA hypomethylation in the origin and pathogenesis of human diseases , 2009, Cellular and Molecular Life Sciences.

[13]  D. Drucker,et al.  Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. , 2009, American journal of physiology. Endocrinology and metabolism.

[14]  B. Maier,et al.  Peroxisome Proliferator-Activated Receptor γ Activation Restores Islet Function in Diabetic Mice through Reduction of Endoplasmic Reticulum Stress and Maintenance of Euchromatin Structure , 2009, Molecular and Cellular Biology.

[15]  Andrew J. Bannister,et al.  Synthetic linear and cyclic glucagon antagonists. , 2009, International journal of peptide and protein research.

[16]  C. Behrens,et al.  Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor. , 2008, Journal of medicinal chemistry.

[17]  V. Ding,et al.  Discovery of potent, orally active benzimidazole glucagon receptor antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[18]  F. Costa,et al.  Non-coding RNAs, epigenetics and complexity. , 2008, Gene.

[19]  C. Everett-Grueter,et al.  A Novel Glucagon Receptor Antagonist, NNC 25-0926, Blunts Hepatic Glucose Production in the Conscious Dog , 2007, Journal of Pharmacology and Experimental Therapeutics.

[20]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[21]  V. Ding,et al.  Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor. , 2007, Bioorganic & medicinal chemistry letters.

[22]  C. Behrens,et al.  New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists , 2007 .

[23]  M. J. Charron,et al.  Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia , 2006, Diabetologia.

[24]  A. Amin,et al.  Vitamin E Decreases the Hyperglucagonemia of Diabetic Rats , 2006, Annals of the New York Academy of Sciences.

[25]  B. Desbuquois,et al.  Glucagon‐mediated internalization of serine‐phosphorylated glucagon receptor and Gsα in rat liver , 2006, FEBS letters.

[26]  J. Holst,et al.  Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice , 2006, Diabetes.

[27]  V. Ding,et al.  Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[28]  V. Ding,et al.  Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor. , 2005, Bioorganic & medicinal chemistry letters.

[29]  D. Moller,et al.  A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. , 2004, Diabetes.

[30]  J. Fenyk-Melody,et al.  Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. , 2004, European journal of pharmacology.

[31]  G. Gemmecker,et al.  BI-32169, a bicyclic 19-peptide with strong glucagon receptor antagonist activity from Streptomyces sp. , 2004, Journal of natural products.

[32]  J. Gromada,et al.  Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. , 2004, The Journal of clinical investigation.

[33]  Jyoti R. Patel,et al.  Biaryl amide glucagon receptor antagonists. , 2004, Bioorganic & medicinal chemistry letters.

[34]  C. Rhodes,et al.  Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells , 2004, Diabetologia.

[35]  M. Mor,et al.  Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists. , 2004, Bioorganic & medicinal chemistry.

[36]  B. Monia,et al.  Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. , 2004, Diabetes.

[37]  Bei B. Zhang,et al.  Glucagon and regulation of glucose metabolism. , 2003, American journal of physiology. Endocrinology and metabolism.

[38]  J. Holst,et al.  Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Livingston,et al.  Discovery of 5‐Hydroxyalkyl‐4‐phenylpyridines as a New Class of Glucagon Receptor Antagonists. , 2002 .

[40]  A. Kuki,et al.  Human glucagon receptor antagonists based on alkylidene hydrazides. , 2002, Bioorganic & medicinal chemistry letters.

[41]  J. Stock,et al.  Glycemic control in mice with targeted disruption of the glucagon receptor gene. , 2002, Biochemical and biophysical research communications.

[42]  K. Petersen,et al.  Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans , 2001, Diabetologia.

[43]  A. Kuki,et al.  Identification of alkylidene hydrazides as glucagon receptor antagonists. , 2001, Journal of medicinal chemistry.

[44]  V. Hruby,et al.  Development of potent glucagon antagonists: structure-activity relationship study of glycine at position 4. , 2001, The journal of peptide research : official journal of the American Peptide Society.

[45]  Carolyn B Levy,et al.  Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. , 2000, Diabetes.

[46]  R. Rizza,et al.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. , 2000, The Journal of clinical endocrinology and metabolism.

[47]  A. Ponery,et al.  Distribution of NPY and SP and their effects on glucagon secretion from the in vitro normal and diabetic pancreatic tissues☆ , 2000, Peptides.

[48]  D. Moller,et al.  New approaches in the treatment of type 2 diabetes. , 2000, Current opinion in chemical biology.

[49]  Howard Y. Chen,et al.  Generation of mice expressing the human glucagon receptor with a direct replacement vector , 1999, Transgenic Research.

[50]  R. Rizza,et al.  Impact of lack of suppression of glucagon on glucose tolerance in humans. , 1999, American journal of physiology. Endocrinology and metabolism.

[51]  M. Maccoss,et al.  Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor* , 1999, The Journal of Biological Chemistry.

[52]  R. Burcelin,et al.  Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. , 1996, Diabetes & metabolism.

[53]  D.,et al.  Low Level Cyclic Adenosine 3’,5’-Monophosphate Accumulation Analysis of [des-His’,des-Phe’,Glu’]Glucagon-NH, Identifies Glucagon Antagonists from Weak Partial Agonists/Antagonists* , 2001 .

[54]  I. Svendsen,et al.  Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits , 1996, Diabetes.

[55]  E. Nishimura,et al.  Glucagon receptor mRNA distribution in rat tissues , 1995, Peptides.

[56]  J. Holst,et al.  Role of glucagon in maintenance of euglycemia in fed and fasted rats. , 1995, The American journal of physiology.

[57]  J. Holst,et al.  Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats , 1994, Diabetologia.

[58]  F. Grant,et al.  The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. , 1994, Gene.

[59]  R. B. Merrifield,et al.  Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist , 1989, Peptides.

[60]  Nozawa Yoshinori,et al.  A comparative study on cytotoxicities and biochemical properties of anthraquinone mycotoxins emodin and skyrin from Penicillium islandicum Sopp. , 1984 .

[61]  V. Hruby.  Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs , 1982, Molecular and Cellular Biochemistry.

[62]  V. Hruby,et al.  Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. , 1982, Science.

[63]  L. Birnbaumer,et al.  The glucagon-sensitive adenylate cyclase system in plasma membranes of rat liver. VII. Hormonal stimulation: reversibility and dependence on concentration of free hormone. , 1972, The Journal of biological chemistry.

[64]  L. Birnbaumer,et al.  The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. IV. Effects of guanylnucleotides on binding of 125I-glucagon. , 1971, The Journal of biological chemistry.

[65]  H. Horiuchi.  Seven-transmembrane receptors , 2015 .

[66]  V. Ding,et al.  Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core. , 2011, Bioorganic & medicinal chemistry letters.

[67]  I. Quesada,et al.  REVIEW Physiology of the pancreatic a -cell and glucagon secretion: role in glucose homeostasis and diabetes , 2008 .

[68]  C. Behrens,et al.  New beta-alanine derivatives are orally available glucagon receptor antagonists. , 2007, Journal of medicinal chemistry.

[69]  Y. Zhang,et al.  Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. , 2006, Cell metabolism.

[70]  V. Hruby,et al.  New glucagon analogues with conformational restrictions and altered amphiphilicity: effects on binding, adenylate cyclase and glycogenolytic activities. , 1993, Life sciences.

[71]  Y. Nozawa,et al.  A comparative study on cytotoxicities and biochemical properties of anthraquinone mycotoxins emodin and skyrin from Penicillium islandicum Sopp. , 1984, Toxicology letters.

[72]  J. McGarry,et al.  Regulation of hepatic fatty acid oxidation and ketone body production. , 1980, Annual review of biochemistry.

[73]  D. Drucker,et al.  The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting , 2022 .